Zacks48d agoneutral
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
540last 24h
2526last 7d
484● bullish (7d)
255● bearish (7d)
198publishers
Zacks48d agoneutral
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
Zacks48d agobullish
Biogen to Strengthen Immunology Pipeline With $1B RayThera BuyoutBIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
Insider Monkey49d agoneutral
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals EmergeEli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 3 years. On June 15, Eli Lilly and Company (NYSE:LLY) shared new data from the Phase 1 AJX-101 study. The study showed that an investigational type II JAK2 inhibitor delivered an “encouraging” safety profile, demonstrating clinical activity in […]
Bloomberg49d agoneutralVIDEO
J&J Has No Plans to Enter Obesity Drugs Market, CEO SaysJohnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.
GuruFocus.com49d agoneutral
J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.
Insider Monkey49d agoneutral
Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock”Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted worthy space players and reviewed several of this year’s IPOs. When a caller noted the high share price and ventured a guess that the company might split the stock, Cramer commented: I don’t know if they’re going to […]
Simply Wall St.49d agoneutral
Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug PricingEli Lilly (NYSE:LLY) plans to reduce its previously announced €2.7b investment in Germany by half. The company links the cutback to European drug pricing reforms that it says could affect future R&D and manufacturing commitments. The decision highlights rising friction between large pharmaceutical companies and European governments over efforts to limit healthcare spending. Eli Lilly is a major global pharmaceutical company with a broad portfolio of branded drugs and a pipeline of new...
Trefis49d agoneutral
Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That VanishedManagement once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.
Investing.com49d agoneutral
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO saysInvesting.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.
Insider Monkey49d agoneutral
FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSSEli Lilly and Company (NYSE:LLY) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 9, the US FDA approved a new maintenance dosing regimen for Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), allowing adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every 8 weeks. […]
Motley Fool49d agoneutral
3 Underrated Dividend Stocks That Could Generate Reliable Cash Flow for Your Portfolio for DecadesThese stocks may not be your first choices when looking for dividends, but they have been income-generating machines for years.
Bloomberg49d agoneutral
Snubbing Nvidia for Adobe Costs Florida Stock-Picker $50 Billion(Bloomberg) -- It was 180 degrees off the hot trade on Wall Street. Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingIran’s Deputy Foreign Minister Confirms Deal Reached With USNetanyahu Pays a Political Price for Trump’s Iran DealUS Set to Offer Iran Broad Financial Gains in Peace DealSnub Nvidia Corp., the soaring king of artificial intelligence chips. Embrace Adobe Inc., a sinking casualty of AI disruptio
Reuters Videos49d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing. </p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers. </p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. </p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. </p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. </p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. </p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>
Insider Monkey50d agoneutral
Can Retatrutide Extend Eli Lilly and Co (LLY)’s Lead in Weight Loss Market?Eli Lilly and Co (NYSE:LLY) is one of billionaire Ken Fisher’s top high growth stock picks. In the past month, Lilly shares have gained more than 18%. The shares have soared almost 50% over the past year. On June 6, Eli Lilly and Co (NYSE:LLY) presented results from late-stage trials of its weight-loss drug candidate, […]
GuruFocus.com50d agoneutral
Novo Nordisk to File Oral Wegovy in ChinaCEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in "a few months"
TheStreet50d agoneutral
Eli Lilly’s hottest drugs face a quiet new threatEli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...
MT Newswires50d agoneutral
Sector Update: Healthcare Stocks Advance in Afternoon TradingHealthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree
Motley Fool50d agoneutral
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?These two healthcare leaders have a long history of competing against one another.
Barrons.com50d agoneutral
Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.Eli Lilly is acquiring Austin-based 4E Therapeutics, the developer of non-addictive painkillers, for an undisclosed amount.
The Wall Street Journal50d agoneutral
Health Care Roundup: Market TalkGain insight on Roche, Zealand Pharma and more in the latest Market Talks covering the health care sector.
MT Newswires50d agoneutral
European Stocks Higher in Tuesday Trading; Markets Buoyed by US, Iran Peace Deal; Inflation Remains a ConcernThe European stock markets were modestly higher in Tuesday trading as the markets reacted positively
Simply Wall St.50d agobullish
Eli Lilly (LLY) Buys 4E Therapeutics As Jaypirca Hits Key Leukemia MilestoneEli Lilly (NYSE:LLY) is acquiring 4E Therapeutics, adding MNK inhibitor candidates aimed at non opioid chronic pain treatment. The deal expands Lilly's neuroscience pipeline beyond its existing focus on metabolic and diabetes therapies. Jaypirca has reached a key clinical milestone in the Phase 3 BRUIN CLL-322 trial in relapsed or refractory chronic lymphocytic leukemia when used with venetoclax and rituximab. These developments represent fresh, material updates for Eli Lilly that relate...
Zacks50d agoneutral
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.
Motley Fool50d agoneutral
Health Care ETFs: XLV Delivers Low Fees and Solid ReturnsExplore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.
GuruFocus.com50d agoneutral
Novo Seeks China Approval for Wegovy PillThe move could expand Novo's reach in a key obesity-drug market.
BioPharma Dive50d agobullish
Lilly buys non-opioid pain drugmaker 4EIt’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.